An important aspect of therapy with radionuclides is biodistribution of the radio-pharmaceutical. While high target tissue binding is the most important goal, nonspecific binding or blood pool residence of the compound is an important consideration. Also important is the biodistribution of metabolized components and their excretion routes. Ideally, a therapeutic radiopharmaceutical has high target binding and rapid excretion without redistribution to nontarget tissues and compartments. A major responsibility of the nuclear medicine physician is to know and understand completely the biodistribution patterns of a radionuclide therapy combination. Not only is this important for safety, but for accurate dosimetry estimation. Often, observation of biodistribution requires imaging and quantification of radionuclide tissue concentration and time-activity data (3). Additionally, knowledge of the biodistribution of the pharmaceutical that will be radiolabeled will give an indication of the correct radioisotope to be chosen for the therapy indication.

0 0

Post a comment